Tyrosine kinase inhibitors

Details Tyrosine kinase inhibitors Tyrosine kinase inhibitors

2006-10-24

2006-10-24

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S300000, C514S218000, C514S231500, C514S253040, C544S362000, C544S106000, C540S489000, C546S121000

Reexamination Certificate

active

07125888

ABSTRACT:
The present invention relates to imidazopyridine compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

REFERENCES:
patent: 3734923 (1973-05-01), Dowding et al.
patent: 3755347 (1973-08-01), Guillot et al.
patent: 5480883 (1996-01-01), Spada et al.
patent: 6872731 (2005-03-01), Crawforth et al.
patent: 451 156 (1968-05-01), None
patent: 0 069 784 (1982-05-01), None
patent: 0 069 784 (1987-12-01), None
patent: 0 928 790 (1999-07-01), None
patent: 7 428 (1969-12-01), None
patent: 2 252 808 (1975-06-01), None
patent: WO 95 09852 (1995-04-01), None
patent: WO 99 62890 (1999-12-01), None
patent: WO 00 02871 (2000-01-01), None
patent: WO 00 26203 (2000-05-01), None
patent: WO 01 17995 (2001-03-01), None
patent: WO 02 45652 (2002-06-01), None
patent: WO 03 000687 (2003-01-01), None
patent: WO 03 015717 (2003-02-01), None
STN result (accession No. 1955:35987).
Spada et al., CAS Document No. 124:261073.
Lawrence & Niu, Protein Kinase Inhibitors: the Tyrosine-Specific Protein Kinases Pharmacol. Ther. 77(2):81-114 (1998).
Rossberg & Magun, Piezoelectricity of Ice, NATURWISSENSCHAFTEN 44:59 (1957).
Gol'dfarb & Kondkova, Synthesis of carbazi-condensed systems form α-and α′-aminonicotines, Zhurnal Prikladnoi Khimi 15:151-63 (1942).
Hu et al., Solubale Vascular Endothelial Growth Factor Receptor 1, and Not Receptor 2, Is an Independent Prognostic Factor in Acute Myeloid Leukemia and Myelodysplastic Syndromes, CANCER, 100(9):1884-91 (2004).
Meshinchi et al., Activating Mutations of RTK/ras Signal Transduction Pathway in Pediatric Acute Myeloid Leukemia, Blood, 102(4):1474-1479 (2003).
Schuch et al., In vivo Administration of Vascular Endothelial Growth Factor )VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the Progression of Acute Myeloid Leukemia in vivo, BLOOD, 100(13):4622-4628 (2002).
J. Rak et al. Cancer Research, 55:4575-4580, 1995.
G. Gasparini and A.L. Harris, J. Clin. Oncol., 1995, 13:765-782.
M. Toi et al., Japan. J. Cancer Res., 1994, 85:1045-1049.
A.J. Dickinson et al., Br. J. Urol., 1994, 74:762-766.
L.M. Ellis et al., Surgery, 1996, 120(5):871-878.
J.K. Williams et al., Am. J. Surg., 1994, 168:373-380.
A. Amirkhosravi et al., Platelets, 10:285-292 (1999).
S.P. Gunningham, et al., Can. Research, 61: 3206-3211 (2001).
A. Giatromanolaki et al., J. Pathol. 2001; 194:101-108.
Michael Detmar, J. Dermatological Sci., 24 Suppl. 1, S78-S84 (2000).
Hasegawa et al., Skeletal Radiol., vol. 28, pp. 41-45, 1999.
Brockelsby et al., Laboratory Investigation 79:1101-1111 (Sep. 1999).
Paul et al., Nature Med 7:222-227 (2001).
Matsuyama et al., J. Neurol. Sci. 186:75-79 (2001).
van der Flier et al., J. Infectious Diseases. 183:149-153 (2001).
Stephen K. Smith, Trends in Endocrinology & Metabolism, vol. 12, No. 4, pp. 147-151, May/Jun. 2001.
Levis et al., Blood, vol. 98, No. 3, pp. 885-887 (2001).
Rajesh K. Jain, Nature Medicine, vol. 7. No. 9, pp. 987-989 (Sep. 2001).
Giulio Jori, Lasers Med. Sci., 1990; 5: 115-120.
Chuannong Zhou, J. Photochem. and Photobiol. 1989; 3:299-318.
Hendrich et al., Knee Surg Sports Traumatol Arthroscopy 5: 58-63 (1997).
Hall et al., Am J Hum Genet 61:785-789, 1997.
Li et al., Gene Therapy, 1998; 5:1105-13.
Fathallah-Shaykh et al., J Immunol 2000; 164:217-222.
Dougherty et al., J. Natl. Cancer Inst., 1998, 90(12): 889-905.
Van Bruggen et al., J. Clin. Invest,. 104:1613-1620 (1999).
Gerber et al., Nature Medicine, vol. 5, No. 6, pp. 623-628, 1999.
David A. Greenberg, Drug News Perspect 11(5):265-270 (1998).
Nakagawa et al., FEBS Let. 473:161-164 (2000).
Peter Traxler, Exp. Opin. Ther. Patents 8 (12) 1599-1625(1998).
Peter M. Traxler, Exp. Opin. Ther. Patents 7(6) 571-588 (1997).
Joseph V. Simone, Cecil Textbook of Medicine 20th Edition, vol. 1, pp. 1004-1010 (1996).
Lawrence et al., Pub Med Abstract, vol. 77(2), pp. 81-114 (1998).
Cuckler, et al., Nithiazide I. Chemical and Biological Studies, vol. 92, pp. 483-488 (1956).
Nagano, et al., Studies on Organic Sulfur Compounds, vol. 21, pp. 2408-2416 (1973).
Werbel, et al., Journal of Medicinal Chemistry, vol. 15, No. 9 pp. 955-963 (1972).
Micich, et al., Journal of the American Oil Chemists' Society, vol. 59, No. 10 pp. 448-452 (1982).
Wu, et al., Bio & Med Chem Letters, vol. 14, pp. 909-912 (2004).

Affiliated with

Also associated with

Rating

Tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tyrosine kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3644545